Heparin Octasaccharides Inhibit Angiogenesis In vivo

• Published in: Clinical cancer research Vol. 11; no. 22; pp. 8172 - 8179
• Main Authors: Hasan, Jurjees, Shnyder, Steven D., Clamp, Andrew R., McGown, Alan T., Bicknell, Roy, Presta, Marco, Bibby, Michael, Double, John, Craig, Steven, Leeming, David, Stevenson, Kenneth, Gallagher, John T., Jayson, Gordon C.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.11.2005
• Subjects: Angiogenesis; Angiogenesis Inhibitors - pharmacology; Animals; Anticoagulants - pharmacology; Antineoplastic agents; Biological and medical sciences; Cell Line, Tumor; Female; FGF; Fibroblast Growth Factor 2 - pharmacology; Heparin; Heparin - chemistry; Heparin - pharmacology; Humans; Lung Neoplasms - blood supply; Lung Neoplasms - pathology; Lung Neoplasms - prevention & control; Male; Medical sciences; Mice; Mice, Inbred C57BL; Mice, Nude; Neovascularization, Pathologic - prevention & control; Neovascularization, Physiologic - drug effects; Oligosaccharides - pharmacology; Partial Thromboplastin Time; Pharmacology. Drug treatments; Xenograft Model Antitumor Assays - instrumentation; Xenograft Model Antitumor Assays - methods; Angiogenesis; In vivo; Glycosaminoglycan; Anticoagulant; Inhibitor; Heparin; Neovascularization

Background: In previous experiments, we showed that heparin oligosaccharides inhibit the angiogenic cytokine fibroblast growth factor-2. Here, we present the first in vivo study of size-fractionated heparin oligosaccharides in four models of angiogenesis that are progressively less dependent on fibr...